Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(19):1426; doi:10.1093/jnci/djj388
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mera, R.
Right arrow Articles by Correa, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mera, R.
Right arrow Articles by Correa, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

CORRESPONDENCE

Re: Randomized Double-Blind Factorial Trial of Three Treatments to Reduce the Prevalence of Precancerous Gastric Lesions

Robertino Mera, Elizabeth T. H. Fontham, Luis E. Bravo, Juan C. Bravo, M. Blanca Piazuelo, M. Constanza Camargo, Pelayo Correa

Affiliations of authors: Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN (RM, MBP, MCC, PC); School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ETHF); Department of Pathology, Universidad del Valle, Cali, Colombia (LEB, JCB)

Correspondence to: Pelayo Correa, MD, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, 2215 Garland Ave., 1030 MRB IV, Nashville, TN 37232-0252 (e-mail: pelayo.correa@vanderbilt.edu).

The first 10% of the full text of this article appears below.

We congratulate You et al. (1) for the successful completion of their chemoprevention trial. Their results have clear implications for gastric cancer prevention. As emphasized by the authors, all available reports conclude that curing Helicobacter pylori infection is a promising strategy to control gastric cancer. Previously, we supplied the authors with raw data from our . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C.-W. Lee, B. Rickman, A. B. Rogers, S. Muthupalani, S. Takaishi, P. Yang, T. C. Wang, and J. G. Fox
Combination of Sulindac and Antimicrobial Eradication of Helicobacter pylori Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice
Cancer Res., October 15, 2009; 69(20): 8166 - 8174.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-W. Lee, B. Rickman, A. B. Rogers, Z. Ge, T. C. Wang, and J. G. Fox
Helicobacter pylori Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice
Cancer Res., May 1, 2008; 68(9): 3540 - 3548.
[Abstract] [Full Text] [PDF]